A Phase II, Open-Label Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2017
Price : $35 *
At a glance
- Drugs Burixafor (Primary) ; Granulocyte colony-stimulating factors
- Indications Stem cell mobilisation
- Focus Therapeutic Use
- Sponsors TaiGen Biotechnology
- 31 Aug 2018 Biomarkers information updated
- 11 Jan 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 12 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.